Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Adolescent
Adult
Child
Humans
Acquired Immunodeficiency Syndrome
/ drug therapy
AIDS-Related Opportunistic Infections
/ drug therapy
Anti-HIV Agents
/ therapeutic use
Anti-Retroviral Agents
/ therapeutic use
COVID-19
Hepatitis C
/ drug therapy
HIV Infections
/ drug therapy
Lamivudine
/ therapeutic use
Tenofovir
/ therapeutic use
Practice Guidelines as Topic
ART
EACS
European AIDS Clinical
HIV
Mpox
V12.0
antiretorviral therapy
guidelines
major updates
society
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
01
08
2023
accepted:
29
08
2023
medline:
16
11
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated. Version 12.0 of the guidelines recommend the same six first-line treatment options for antiretroviral treatment (ART)-naïve adults as versions 11.0 and 11.1: tenofovir-based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long-acting section has been expanded in the ART and drug-drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti-infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient-reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir-free two-drug regimens in people with isolated anti-hepatitis B core antibodies are provided. In the opportunistic infections and COVID-19 panel, guidance on the management of COVID-19 in people with HIV has been updated according to the most up-to-date evidence, and a new section on monkeypox has been added. In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.
Sections du résumé
BACKGROUND
BACKGROUND
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
KEY POINTS OF THE GUIDELINES UPDATE
UNASSIGNED
Version 12.0 of the guidelines recommend the same six first-line treatment options for antiretroviral treatment (ART)-naïve adults as versions 11.0 and 11.1: tenofovir-based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long-acting section has been expanded in the ART and drug-drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti-infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient-reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir-free two-drug regimens in people with isolated anti-hepatitis B core antibodies are provided. In the opportunistic infections and COVID-19 panel, guidance on the management of COVID-19 in people with HIV has been updated according to the most up-to-date evidence, and a new section on monkeypox has been added.
CONCLUSIONS
CONCLUSIONS
In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Lamivudine
2T8Q726O95
Tenofovir
99YXE507IL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1126-1136Informations de copyright
© 2023 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Ryom L, De Miguel R, Cotter AG, et al. Major revision version 11.0 of the European AIDS clinical society guidelines 2021. HIV Med. 2022;23:849-858.
https://www.eacsociety.org/guidelines/eacs-guidelines/.
Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and Rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 (HIV-1) infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023;76:1646-1654. doi:10.1093/cid/ciad020
Orkin C, Schapiro JM, Perno CF, et al. Expanded multivariable models to assist patient selection for long-acting cabotegravir + Rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis. 2023. doi:10.1093/cid/ciad370
Chinula L, Ziemba L, Brummel S, et al. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023;10:e363-e374.
Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385:595-608.
O'’Mahony O'SD, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people. Age Ageing. 2015;44:213-218.
Lazarus JV, Safreed-Harmon K, Barton SE, et al. Beyond viral suppression of HIV - the new quality of life frontier. BMC Med. 2016;14:94.
Nightingale S, Ances B, Cinque P, et al. Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol. 2023;19:424-433.
Surial B, Ramírez Mena A, Roumet M, et al. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection. J Hepatol. 2023;78:947-957.
Recently acquired and early chronic hepatitis C in MSM: recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. Aids. 2020;34:1699-1711.
Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401:939-949.
Prosty C, Hanula R, Levin Y, Bogoch II, McDonald EG, Lee TC. Revisiting the evidence base for modern-day practice of the treatment of Toxoplasmic encephalitis: a systematic review and meta-analysis. Clin Infect Dis. 2023;76:e1302-e1319.
Guidelines for diagnosing. Preventing and Managing Cryptococcal Disease among Adults, Adolescents and Children Living with HIV. World Health Organization; 2022 Licence: CC BY-NC-SA 3.0 IGO.
Burza S, Mahajan R, Kazmi S, et al. AmBisome monotherapy and combination AmBisome-Miltefosine therapy for the treatment of visceral leishmaniasis in patients coinfected with human immunodeficiency virus in India: a randomized open-label, parallel-arm, phase 3 trial. Clin Infect Dis. 2022;75:1423-1432.
WHO. Guidelines for the Treatment of Visceral Leishmaniasis in HIV co-Infected Patients in East Africa and South-East Asia. World Health Organization; 2022 Licence: CC BY-NC-SA 3.0 IGO.
Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487-2498.
Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (hiv)-associated tuberculous meningitis. Clin Infect Dis. 2011;52:1374-1383.
Ingle SM, Miro JM, May MT, et al. Early antiretroviral therapy not associated with higher cryptococcal meningitis mortality in people with HIV in high-income countries: an international collaborative cohort study. Clin Infect Dis. 2023;77:64-73.
https://penta-id.org/hiv/treatment-guidelines/.
Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;3018:1-13. doi:10.1016/S2352-3018(23)00028-0